Fig. 4: Binding characteristics of D11 and E07 mAbs to Gal-3, Gal-1, and Gal-7.
From: Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis
a Binding of D11 and E07 mAbs to human (h) and mouse (m) Gal-3 constructs (FL, full-length; CRD, carbohydrate recognition domain) and their selectivity towards human Gal-1 and Gal-7, measured by ELISA. Each mAb (D11, red; E07, blue) was tested at 20 µg/mL, and the appropriate positive control (commercial antibody against Gal-3, Gal-1, or Gal-7; Ctrl, gray bars) was used at 5 µg/mL. An irrelevant IgG (Irr) was used as a negative control for each assay. b Dose–response ELISA of D11 and E07 mAbs binding to hGal-3 (solid lines) and mGal-3 (dotted lines). c Dose–response competition between asialofetuin (ASF) and D11 and E07 mAbs to hGal-3. d KD values of D11 and E07 mAbs to recombinant Gal-3 from multiple species (h, human; m, mouse; r, rat; c, cynomolgus; d, dog) by SPR. Data are representative of one experiment performed during the anti-Gal-3 IgG selection flow scheme.
